Warfarin versus aspirin: Using CHADS2 to guide therapy for stroke prevention in nonvalvular atrial fibrillation

Consultant Pharmacist

Volumn 24, Issue 11, 2009, Pages 841-844

  Hopps, Sarah ^a   Marcy, Todd R ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

Author keywords

Aspirin; Atrial fibrillation; CHADS2; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; PLACEBO; WARFARIN;

AGED; BLEEDING; CASE REPORT; CEREBROVASCULAR ACCIDENT; DRUG MONITORING; DRUG USE; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MALE; PHYSICIAN; PROPHYLAXIS; RECOMMENDED DRUG DOSE; RISK; RISK ASSESSMENT; SCORING SYSTEM; SHORT SURVEY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; DRUG MONITORING; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; RISK ASSESSMENT; RISK FACTORS; STROKE; WARFARIN;

EID: 70450248370     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2009.841     Document Type: Short Survey

References (10)

1. Hobbs FD, Fitzmaurice DA, Murray E et al. A randomized controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over (SAFE study). Health Technol Assess 2005;9:1-74.
2. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation. Chest 2008;133 Suppl 6:546-592
3. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870 (Pubitemid 32537350)
4. Hylek EM, Skates SJ, Sheehan MA et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546
5. Gage BF, Birman-Deych E, Kerzner R et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005;118:612-617 (Pubitemid 40732700)
6. Go AS, Hylek EM, Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA 2003;290:2685-2692
7. Lip, GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006;118:321-333
8. Van Walraven C, Hart RG, Singer DE et al. Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation: an individual patient metaanalysis. JAMA 2002;288:2441-2448
9. Gage BF, Van Walraven, C. Pearce L et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-2292 (Pubitemid 39407328)
10. Schulman S, Beyth RJ, Kearon C et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment. Chest 2008;133 Suppl 6:257-298